Predictive value of immune-modified Glasgow prognostic score in patients with head and neck squamous cell carcinoma treated with nivolumab.

IF 0.8 4区医学 Q3 OTORHINOLARYNGOLOGY

Journal of Laryngology and Otology Pub Date : 2025-07-14 DOI:10.1017/S0022215125102612

Toshimitsu Ohashi, Nansei Yamada, Kosuke Terazawa, Hirofumi Shibata, Masato Takiwaki, Takanori Wakaoka, Shigeaki Tanahasi, Hiroki Takahashi, Bunya Kuze, Masami Ohnishi, Hiromichi Shirato, Keisuke Mizuta, Takenori Ogawa

{"title":"Predictive value of immune-modified Glasgow prognostic score in patients with head and neck squamous cell carcinoma treated with nivolumab.","authors":"Toshimitsu Ohashi, Nansei Yamada, Kosuke Terazawa, Hirofumi Shibata, Masato Takiwaki, Takanori Wakaoka, Shigeaki Tanahasi, Hiroki Takahashi, Bunya Kuze, Masami Ohnishi, Hiromichi Shirato, Keisuke Mizuta, Takenori Ogawa","doi":"10.1017/S0022215125102612","DOIUrl":null,"url":null,"abstract":"Objectives: The immune-modified Glasgow Prognostic Score, encompassing C-reactive protein, serum albumin, and lymphocyte count, is a valuable prognostic tool for head and neck squamous cell carcinoma. We aimed to assess the utility of immune-modified Glasgow Prognostic Score in predicting the treatment response to nivolumab in patients with head and neck squamous cell carcinoma.Methods: Seventy-six patients with head and neck squamous cell carcinoma treated with nivolumab were included in this study. The imGPS was assessed before the initial nivolumab dose and four weeks after immune-modified Glasgow Prognostic Score.Results: Multivariable analysis identified four weeks after immune-modified Glasgow Prognostic Score as an adverse prognostic factor for progression-free and overall survival. The best overall response was significantly associated with four weeks after immune-modified Glasgow Prognostic Score. Remarkably, all patients with four weeks after immune-modified Glasgow Prognostic Score = 3 and 8 (80.0%) of 10 patients with four weeks after immune-modified Glasgow Prognostic Score = 2 experienced progressive disease.Conclusion: The immune-modified Glasgow Prognostic Score proves valuable for predicting prognosis in patients with head and neck squamous cell carcinoma undergoing nivolumab treatment, particularly excelling in identifying individuals unlikely to respond to nivolumab.","PeriodicalId":16293,"journal":{"name":"Journal of Laryngology and Otology","volume":" ","pages":"1-7"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Laryngology and Otology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S0022215125102612","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The immune-modified Glasgow Prognostic Score, encompassing C-reactive protein, serum albumin, and lymphocyte count, is a valuable prognostic tool for head and neck squamous cell carcinoma. We aimed to assess the utility of immune-modified Glasgow Prognostic Score in predicting the treatment response to nivolumab in patients with head and neck squamous cell carcinoma.

Methods: Seventy-six patients with head and neck squamous cell carcinoma treated with nivolumab were included in this study. The imGPS was assessed before the initial nivolumab dose and four weeks after immune-modified Glasgow Prognostic Score.

Results: Multivariable analysis identified four weeks after immune-modified Glasgow Prognostic Score as an adverse prognostic factor for progression-free and overall survival. The best overall response was significantly associated with four weeks after immune-modified Glasgow Prognostic Score. Remarkably, all patients with four weeks after immune-modified Glasgow Prognostic Score = 3 and 8 (80.0%) of 10 patients with four weeks after immune-modified Glasgow Prognostic Score = 2 experienced progressive disease.

Conclusion: The immune-modified Glasgow Prognostic Score proves valuable for predicting prognosis in patients with head and neck squamous cell carcinoma undergoing nivolumab treatment, particularly excelling in identifying individuals unlikely to respond to nivolumab.

查看原文本刊更多论文

免疫修饰格拉斯哥预后评分在纳武单抗治疗头颈部鳞状细胞癌患者中的预测价值。

目的：免疫修饰的格拉斯哥预后评分，包括c反应蛋白、血清白蛋白和淋巴细胞计数，是头颈部鳞状细胞癌的一个有价值的预后工具。我们的目的是评估免疫修饰的格拉斯哥预后评分在预测头颈部鳞状细胞癌患者对纳武单抗治疗反应中的效用。方法：76例接受纳武单抗治疗的头颈部鳞状细胞癌患者纳入本研究。imGPS在初始纳武单抗剂量前和免疫修饰格拉斯哥预后评分后4周进行评估。结果：多变量分析确定免疫修饰的格拉斯哥预后评分4周后为无进展和总生存期的不良预后因素。最佳总体反应与免疫修饰格拉斯哥预后评分后4周显著相关。值得注意的是，免疫修饰的格拉斯哥预后评分= 3后4周的所有患者和免疫修饰的格拉斯哥预后评分= 2后4周的10例患者中有8例（80.0%）出现疾病进展。结论：免疫修饰的格拉斯哥预后评分在预测接受纳武单抗治疗的头颈部鳞状细胞癌患者的预后方面被证明是有价值的，特别是在识别不太可能对纳武单抗有反应的个体方面表现出色。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Laryngology and Otology 医学-耳鼻喉科学

CiteScore

3.20

自引率

11.80%

发文量

593

审稿时长

3-6 weeks

期刊介绍： The Journal of Laryngology & Otology (JLO) is a leading, monthly journal containing original scientific articles and clinical records in otology, rhinology, laryngology and related specialties. Founded in 1887, JLO is absorbing reading for ENT specialists and trainees. The journal has an international outlook with contributions from around the world, relevant to all specialists in this area regardless of the country in which they practise. JLO contains main articles (original, review and historical), case reports and short reports as well as radiology, pathology or oncology in focus, a selection of abstracts, book reviews, letters to the editor, general notes and calendar, operative surgery techniques, and occasional supplements. It is fully illustrated and has become a definitive reference source in this fast-moving subject area. Published monthly an annual subscription is excellent value for money. Included in the subscription is access to the JLO interactive web site with searchable abstract database of the journal archive back to 1887.